ASSESSING THE EFECTS OF MICRODOSING MB22001 IN MENSTRUATING PERSONS WITH AND WITHOUT PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER Multiple clinical trials…
-- The Phase 2b study planned to be conducted in 15 clinical sites in the United States -- -- Topline…
POMPANO BEACH, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused…
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and…
– A-005 is a potential first-in-class, CNS penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – –…
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule…
TAMPA, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first…
Independent Safety Committee approves increase of RECCE® 327 (R327) dose to 4,000mg intravenously (IV) over 30 minutes for six subjects,…
Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals,…
Statistically Significant Improvements with DCCR Compared to Natural History of PWS from the PATH for PWS Study in Hyperphagia and PWS-related…